Development of vitiligo during melanoma treatment with a novel survivin inhibitor: A case report and review of the literature

International Journal of Dermatology

Volumn 48, Issue 4, 2009, Pages 426-430

  Fujita, Mayumi ^a,b   High, Whitney A ^a   Asgari, Shabnam ^a   Lewis, Karl D ^a   Gonzalez, Rene ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; PROTEIN INHIBITOR; SURVIVIN; SURVIVIN INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STAGING; CASE REPORT; CONTINUOUS INFUSION; DEATH; DEPIGMENTATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; IMMUNE RESPONSE; LYMPH NODE METASTASIS; MALE; MELANOMA; PATHOGENESIS; PELVIS LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SKIN BIOPSY; TREATMENT RESPONSE; VITILIGO;

AGED; ANTINEOPLASTIC AGENTS; HUMANS; IMIDAZOLES; MALE; MELANOMA; MICROTUBULE-ASSOCIATED PROTEINS; NAPHTHOQUINONES; SKIN NEOPLASMS; VITILIGO;

EID: 63249122606     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.03987.x     Document Type: Article

References (30)

1. Nordlund JJ, Kirkwood JM, Forget BM, et al. Vitiligo in patients with metastatic melanoma: A good prognostic sign. J Am Acad Dermatol 1983; 9: 689-696.
2. Bystryn JC. Immune mechanisms in vitiligo. Clin Dermatol 1997; 15: 853-861.
3. Richards JM, Mehta N, Ramming K, et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992; 10: 1338-1343.
4. Le Gal FA, Paul C, Chemaly P, et al. More on cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol 1996; 35: 650-651.
5. Boasberg PD, Hoon DS, Piro LD, et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006; 126: 2658-2663.
6. Daneshpazhooh M, Shokoohi A, Dadban A, et al. The course of melanoma-associated vitiligo: Report of a case. Melanoma Res 2006; 16: 371-373.
7. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-718.
8. Schreiber S, Kampgen E, Wagner E, et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study. Hum Gene Ther 1999; 10: 983-993.
9. Trefzer U, Weingart G, Chen Y, et al. Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma. Int J Cancer 2000; 85: 618-626.
10. Luiten RM, Kueter EW, Mooi W, et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 2005; 23: 8978-8991.
11. Yee C, Thompson JA, Roche P, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo. J Exp Med 2000; 192: 1637-1644.
12. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854.
13. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-2357.
14. Smalley KS, Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann NY Acad Sci 2005; 1059: 16-25.
15. Becker JC, Kirkwood JM, Agarwala SS, et al. Molecularly targeted therapy for melanoma: Current reality and future options. Cancer 2006; 107: 2317-2327.
16. Bayes M. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2007; 29: 153-173.
17. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
18. Johnson ME, Howerth EW. Survivin: A bifunctional inhibitor of apoptosis protein. Vet Pathol 2004; 41: 599-607.
19. Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999; 113: 1076-1081.
20. Vetter CS, Muller-Blech K, Schrama D, et al. Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions. Arch Dermatol Res 2005; 297: 26-30.
21. Ding Y, Prieto VG, Zhang PS, et al. Nuclear expression of the antiapoptotic protein survivin in malignant melanoma. Cancer 2006; 106: 1123-1129.
22. Tsao H, Millman P, Linette GP, et al. Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol 2002; 138: 799-802.
23. Powell DJ Jr, Dudley ME, Hogan KA, et al. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 2006; 177: 6527-6539.
24. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100: 8372-8377.
25. Mackensen A, Herbst B, Chen JL, et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 2000; 86: 385-392.
26. Cormier JN, Hijazi YM, Abati A, et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998; 75: 517-524.
27. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-998.
28. Lizee G, Radvanyi LG, Overwijk WW, et al. Immunosuppression in melanoma immunotherapy: Potential opportunities for intervention. Clin Cancer Res 2006; 12: 2359s-2365s.
29. Kornacker M, Verneris MR, Kornacker B, et al. Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol Lett 2001; 76: 169-173.
30. Sharief MK, Semra YK. Heightened expression of survivin in activated T lymphocytes from patients with multiple sclerosis. J Neuroimmunol 2001; 119: 358-364.